MedDataX Logo

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

NCT ID: NCT07285850

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-20

Study Completion Date

2026-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will recruit 20 patients, randomly dividing them into sequential and concurrent groups for up to 6 months of treatment and follow-up. In addition to routine efficacy assessments, the study will analyze changes in the microenvironment before and after treatment, including T-cell calcium levels, VEGFA expression, and immune-related factor alterations. Furthermore, it will explore the relationship between T-cell calcium signaling genes and treatment response, evaluating the impact of baseline metabolic characteristics (such as blood lipids and insulin resistance) on therapeutic outcomes.

In terms of safety, the study will monitor all adverse events (AEs) and serious adverse events (SAEs), and classify them according to the CTCAE 5.0 criteria. During the treatment period, patients will undergo regular liver biopsy to assess changes in the tumor microenvironment. The ultimate goal of the study is to provide evidence-based precision treatment strategies for MASLD-HCC patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HCC - Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Although this study investigates the role of sequential therapy, the experimental design involves two parallel groups. One group receives atezolizumab combined with bevacizumab, while the other group is treated first with bevacizumab followed by sequential administration of atezolizumab. Both groups receive the same drugs, differing only in the sequence of administration.
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

Group Type EXPERIMENTAL

Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

Intervention Type DRUG

The first cycle (3 weeks) receives bevacizumab monotherapy, and from the second cycle onwards, it is combined with atezolizumab until disease progression or intolerable toxicity.

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Group Type ACTIVE_COMPARATOR

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Intervention Type DRUG

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sequential treatment of bevacizumab combined with atezolizumab (sequential group)

The first cycle (3 weeks) receives bevacizumab monotherapy, and from the second cycle onwards, it is combined with atezolizumab until disease progression or intolerable toxicity.

Intervention Type DRUG

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old (gender not limited)
* ECOG performance status of 0-1
* Preoperative imaging diagnosis of advanced hepatocellular carcinoma (BCLC stage C or D, unsuitable for surgery)
* Ultrasound or MRI indicating moderate to severe fatty liver (Fibroscan CAP \> 268 dB/m or MR fat score \> 10%)
* Willing to use contraceptive measures during the trial period
* Expected survival time ≥ 3 months
* At least one measurable lesion (per RECIST 1.1) that has not been irradiated
* Organ function levels (within 7 days before first study medication) must meet the following:
* Hematopoietic function: ANC ≥ 1.5×10⁹/L, PLT ≥ 100×10⁹/L, Hb ≥ 90 g/L, no transfusion within 14 days
* Liver function: TBIL ≤ 1.5×ULN, AST/ALT/ALP ≤ 2.5×ULN, serum creatinine ≤ 1.5×ULN, CrCl ≥ 50 mL/min, ALB ≥ 30 g/L, Child-Pugh A
* Coagulation function: INR and APTT ≤ 1.5×ULN or within therapeutic range if on anticoagulants
* Renal function: urinary protein ≤ 1+ (or ≤1 g/24h if \>1+)
* Cardiac function: ECG normal or clinically insignificant, LVEF \> 50%
* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dosing
* Men and women of reproductive potential must use effective contraception during and for 12 months after treatment
* Participants must voluntarily provide informed consent and have good compliance

Exclusion Criteria

* Excessive alcohol consumption (weekly ethanol intake: males \< 210 g, females \< 140 g)
* Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
* Pregnant or breastfeeding women, or positive pregnancy test at baseline
* Central nervous system metastases diagnosed by CT, MRI, or PET-CT
* Participation in another clinical drug or therapy trial within 4 weeks before first study dose
* Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
* Radiotherapy within 2 weeks before first study dose
* History or presence of primary immunodeficiency or active autoimmune disease
* History of organ transplantation or hematopoietic stem cell transplantation
* Current use of immunosuppressants or corticosteroids (\>10 mg/day prednisone or equivalent) within 2 weeks
* Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection
* Allergy to recombinant humanized PD-1 monoclonal antibody, VEGF monoclonal antibody, or components
* Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
* Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
* Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, TIA, embolism)
* History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
* Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
* Active pulmonary disease (interstitial pneumonia, COPD, asthma, tuberculosis history)
* Abnormal coagulation (INR \> 2.0, PT \> 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
* Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
* Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
* History of substance abuse or mental disorders affecting compliance
* Use of warfarin or coumarin derivatives within 14 days before or during treatment
* Other severe acute/chronic conditions increasing risk or confounding results
* Poor compliance or other conditions deemed unsuitable for trial participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eastern Hepatobiliary Surgery Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shen Feng

Director of Clinical Research Institute

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eastern Hepatobiliary Surgery Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hao Shen, M.D.

Role: CONTACT

[email protected]
18952681068

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hao Shen, Dr

Role: primary

[email protected]
+8616628552926

Hao

Role: backup

[email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

82403243

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

EHBHKY2024-K023-P011

Identifier Type: -

Identifier Source: org_study_id